modules
BRIDGE CAR T
Building Bridges Between Treatment Centers and Community Oncologists to Overcome Barriers in CAR T-Cell Therapy
Series Description
Multiple myeloma (MM) is an incurable plasma cell malignancy with a high burden of relapse and treatment resistance. For patients with relapsed/refractory multiple myeloma (RRMM), chimeric antigen receptor (CAR) T-cell therapies have emerged as a promising treatment approach, offering the potential for deep and durable responses; however, timely referral and coordination between community oncologists and specialized CAR T treatment centers remain significant barriers to patient access. BRIDGE CAR T: Building Bridges Between Treatment Centers and Community Oncologists to Overcome Barriers in CAR T-Cell Therapy is a grassroots CME/CE pilot initiative designed to close these gaps by delivering localized, small-group educational workshops, expert-led discussions, and practical clinician and patient support tools. This multifaceted program will equip community hematologist/oncologists with the latest clinical evidence, real-world insights, and practical strategies for optimizing patient selection, referral, and long-term adverse event (AE) management. By fostering sustained connections between community providers and CAR T treatment centers, BRIDGE CAR T aims to streamline care coordination, enhance provider confidence, and ultimately improve outcomes for patients with RRMM.
Target Audience
This activity will provide continuing medical education (CME) that addresses identified knowledge and practice gaps among community-based hematologist/oncologist clinicians (MDs, APPs and nurses).
Educational Objectives
Workshop 1
After completing this activity, the participant should be better able to:
- Identify patients with RRMM early in the treatment course who may be eligible for referral to CAR T-cell therapy
- Compare the efficacy and safety profiles of FDA-approved CAR T-cell therapy
- Describe the monitoring, mitigation, and management strategies for potential short- and long-term adverse events associated with CAR T-cell therapy
Workshop 2
After completing this activity, the participant should be better able to:
- Identify and manage long-term CAR T-related adverse events in community clinics
- Develop strategies to improve multidisciplinary care coordination between CAR T-cell treatment centers and community sites to overcome barriers associated with CAR T-cell referral and implementation
- Effectively communicate with patients to explain the benefits and risks related to CAR T-cell therapy
CAR T-cell Therapy in MM: Coordination of Care Between Our Center and Yours
